Soleno Therapeutics Inc (NASDAQ:SLNO) shares, rose in value on Wednesday, April 16, with the stock price down by -0.46% to the previous day’s close as strong demand from buyers drove the stock to $69.93.
Actively observing the price movement in the last trading, the stock closed the session at $70.25, falling within a range of $68.46 and $71.0. The value of beta (5-year monthly) was -2.287. Referring to stock’s 52-week performance, its high was $74.00, and the low was $36.61. On the whole, SLNO has fluctuated by 39.55% over the past month.
With the market capitalization of Soleno Therapeutics Inc currently standing at about $3.21 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SLNO’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of SLNO currently trading nearly 10.01% and 29.55% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 62.04, while the 7-day volatility ratio is showing 6.08% which for the 30-day chart, stands at 7.77%. Furthermore, Soleno Therapeutics Inc (SLNO)’s beta value is -2.59, and its average true range (ATR) is 4.86.
A comparison of Soleno Therapeutics Inc (SLNO) with its peers suggests the former has fared considerably weaker in the market. SLNO showed an intraday change of -0.46% in last session, and over the past year, it grew by 81.54%%.
Data on historical trading for Soleno Therapeutics Inc (NASDAQ:SLNO) indicates that the trading volumes over the past 10 days have averaged 1.63 and over the past 3 months, they’ve averaged 1.15 million. According to company’s latest data on outstanding shares, there are 45.70 million shares outstanding.
Nearly 20.63% of Soleno Therapeutics Inc’s shares belong to company insiders and institutional investors own 91.89% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.66 million shares as on 2025-03-31, resulting in a short ratio of 2.52. According to the data, the short interest in Soleno Therapeutics Inc (SLNO) stood at 1505.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 4.81 million. The stock has risen by 55.57% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLNO stock heading into the next quarter.
